CD133+ cells isolated from various sources and their role in future clinical perspectives

Mirella Meregalli, Andrea Farini, Marzia Belicchi, Yvan Torrente

Research output: Contribution to journalArticlepeer-review


Background. CD133 is a member of a novel family of cell surface glycoproteins. Initially, the expression of CD133 antigen was seen only in the hematopoietic derived CD34+ stem cells. At present, CD133 expression is demonstrated in undifferentiated epithelium, different types of tumors and myogenic cells. CD133+ neurosphere cells isolated from brain are able to differentiate into both neurons and glial cells. These data suggested that CD133 could be a specific marker for various stem and progenitor cell populations. Objectives. The main goal would be to describe the role for CD133 as a marker of stem cells able to engraft and differentiate, to form functional non-hematopoietic adult lineages and contribute to disease amelioration via tissue regeneration. Results/conclusion. In conclusion, since the rise of CD133 antigen as a suitable stem cell marker, the possible use of CD133+ stem cells in therapeutic applications has opened a new promising field in the treatment of degenerating diseases. The human circulating cells expressing the CD133 antigen behave as a stem cell population capable of commitment to hematopoietic, endothelial and myogenic lineages. CD133 cell therapy may represent a promising treatment for many diseases.

Original languageEnglish
Pages (from-to)1521-1528
Number of pages8
JournalExpert Opinion on Biological Therapy
Issue number11
Publication statusPublished - Nov 2010


  • CD133
  • DMD
  • Prominin-1
  • Stem cells

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery


Dive into the research topics of 'CD133+ cells isolated from various sources and their role in future clinical perspectives'. Together they form a unique fingerprint.

Cite this